title: Late restenosis following placement of a sirolimus eluting stent for in-stent restenosis.
abstract: Drug eluting stents (DES) are rapidly replacing intravascular brachytherapy for the treatment of bare metal in-stent restenosis (ISR). To date, there are no long-term follow up data supporting this practise. We report symptomatic repeat in-stent restenosis occurring 27 months after sirolimus eluting stent deployment for de novo in-stent restenosis. This case suggests that in a subgroup of patients with ISR, as with brachytherapy, the drug eluting stent may be simply delaying rather than inhibiting the restenotic process.
authors.affiliation: Department of Cardiology, Concord Repatriation General Hospital, Concord, NSW, Australia.
authors.forename: Onn Akbar
authors.initials: OA
authors.lastname: Ali
authors.forename: Harry
authors.initials: H
authors.lastname: Lowe
authors.forename: Leonard
authors.initials: L
authors.lastname: Kritharides
authors.forename: David
authors.initials: D
authors.lastname: Brieger
mesh_terms: D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000601:surgery*; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011475:Prosthesis Failure; D012086:Reoperation; D020123:Sirolimus / Q000494:pharmacology*; D015607:Stents; D013997:Time Factors
chemical_list: D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus